Abstract：
UNASSIGNED: Buvidal is the only depot buprenorphine currently available in Europe. Buvidal offers a new treatment paradigm, which may require some adjustment in the national regulatory frameworks for opioid agonist treatments (OATs), as well as the national care systems.
UNASSIGNED: Data on the national dissemination of Buvidal, types of populations treated, and the national regulatory framework and care organization system through which Buvidal has been implemented were compared between the UK, Finland, Spain, and France, using a qualitative survey.
UNASSIGNED: In 2022, the proportion of people on OAT who received Buvidal was 2.1% in the UK, 60-65% in Finland, 1% in Spain, and 0.3% in France. In both Finland and the UK, the cost of the medication is covered by the national health system, whereas, in Spain and France, Buvidal is accessible only in specialized centers, which must carry its cost. Other national features may explain the gaps in Buvidal use, including the baseline level of OAT coverage, which was high in both France and Spain.
UNASSIGNED: Important national discrepancies are found regarding Buvidal dissemination among people on OAT.
UNASSIGNED: Data on the national dissemination of Buvidal, types of populations treated, and the national regulatory framework and care organization system through which Buvidal has been implemented were compared between the UK, Finland, Spain, and France, using a qualitative survey.
UNASSIGNED: In 2022, the proportion of people on OAT who received Buvidal was 2.1% in the UK, 60-65% in Finland, 1% in Spain, and 0.3% in France. In both Finland and the UK, the cost of the medication is covered by the national health system, whereas, in Spain and France, Buvidal is accessible only in specialized centers, which must carry its cost. Other national features may explain the gaps in Buvidal use, including the baseline level of OAT coverage, which was high in both France and Spain.
UNASSIGNED: Important national discrepancies are found regarding Buvidal dissemination among people on OAT.
摘要：
■Buvidal是目前在欧洲唯一可用的丁丙诺啡。Buvidal提供了一种新的治疗模式，这可能需要对阿片类药物激动剂治疗(OATs)的国家监管框架进行一些调整，以及国家护理系统。
■关于Buvidal在全国传播的数据，被治疗的人群类型，与英国实施Buvidal的国家监管框架和护理组织体系进行了比较，芬兰,西班牙,和法国,使用定性调查。
■2022年，在英国，接受Buvidal的OAT人数比例为2.1％，60-65%在芬兰，西班牙1%,法国为0.3%。在芬兰和英国，药物费用由国家卫生系统承担，然而,在西班牙和法国，Buvidal只能在专业中心访问，必须承担其成本。其他国家特征可以解释Buvidal使用的差距，包括OAT覆盖率的基线水平，这在法国和西班牙都很高。
■在OAT上发现关于Buvidal传播的重要国家差异。
■关于Buvidal在全国传播的数据，被治疗的人群类型，与英国实施Buvidal的国家监管框架和护理组织体系进行了比较，芬兰,西班牙,和法国,使用定性调查。
■2022年，在英国，接受Buvidal的OAT人数比例为2.1％，60-65%在芬兰，西班牙1%,法国为0.3%。在芬兰和英国，药物费用由国家卫生系统承担，然而,在西班牙和法国，Buvidal只能在专业中心访问，必须承担其成本。其他国家特征可以解释Buvidal使用的差距，包括OAT覆盖率的基线水平，这在法国和西班牙都很高。
■在OAT上发现关于Buvidal传播的重要国家差异。
